315 related articles for article (PubMed ID: 19268437)
1. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA
Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry.
Kitagawa T; Ishige N; Suzuki K; Owada M; Ohashi T; Kobayashi M; Eto Y; Tanaka A; Mills K; Winchester B; Keutzer J
Mol Genet Metab; 2005 Jul; 85(3):196-202. PubMed ID: 15979031
[TBL] [Abstract][Full Text] [Related]
3. Determination of globotriaosylceramide in plasma and urine by mass spectrometry.
Krüger R; Bruns K; Grünhage S; Rossmann H; Reinke J; Beck M; Lackner KJ
Clin Chem Lab Med; 2010 Feb; 48(2):189-98. PubMed ID: 19958207
[TBL] [Abstract][Full Text] [Related]
4. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
5. Targeted urine microscopy in Anderson-Fabry disease: a cheap, sensitive and specific diagnostic technique.
Selvarajah M; Nicholls K; Hewitson TD; Becker GJ
Nephrol Dial Transplant; 2011 Oct; 26(10):3195-202. PubMed ID: 21382994
[TBL] [Abstract][Full Text] [Related]
6. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
[TBL] [Abstract][Full Text] [Related]
7. Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease.
Boscaro F; Pieraccini G; la Marca G; Bartolucci G; Luceri C; Luceri F; Moneti G
Rapid Commun Mass Spectrom; 2002; 16(16):1507-14. PubMed ID: 12203240
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
[TBL] [Abstract][Full Text] [Related]
9. Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry.
Krüger R; Tholey A; Jakoby T; Vogelsberger R; Mönnikes R; Rossmann H; Beck M; Lackner KJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 883-884():128-35. PubMed ID: 22138589
[TBL] [Abstract][Full Text] [Related]
10. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease.
Auray-Blais C; Cyr D; Ntwari A; West ML; Cox-Brinkman J; Bichet DG; Germain DP; Laframboise R; Melançon SB; Stockley T; Clarke JT; Drouin R
Mol Genet Metab; 2008 Mar; 93(3):331-40. PubMed ID: 18023222
[TBL] [Abstract][Full Text] [Related]
11. Optimisation of the separation of four major neutral glycosphingolipids: application to a rapid and simple detection of urinary globotriaosylceramide in Fabry disease.
Roy S; Gaudin K; Germain DP; Baillet A; Prognon P; Chaminade P
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jun; 805(2):331-7. PubMed ID: 15135109
[TBL] [Abstract][Full Text] [Related]
12. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients.
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Clin Chim Acta; 2016 Jan; 452():191-8. PubMed ID: 26593248
[TBL] [Abstract][Full Text] [Related]
13. High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Curr Protoc Hum Genet; 2016 Oct; 91():17.24.1-17.24.11. PubMed ID: 27727434
[TBL] [Abstract][Full Text] [Related]
14. Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study.
Paschke E; Fauler G; Winkler H; Schlagenhauf A; Plecko B; Erwa W; Breunig F; Urban W; Vujkovac B; Sunder-Plassmann G; Kotanko P
Am J Kidney Dis; 2011 May; 57(5):673-81. PubMed ID: 21186071
[TBL] [Abstract][Full Text] [Related]
15. Fabry disease: perspectives of urinary proteomics.
Cuccurullo M; Beneduci A; Anand S; Mignani R; Cianciaruso B; Bachi A; Capasso G
J Nephrol; 2010; 23 Suppl 16():S199-212. PubMed ID: 21170881
[TBL] [Abstract][Full Text] [Related]
16. Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients.
Boutin M; Menkovic I; Martineau T; Vaillancourt-Lavigueur V; Toupin A; Auray-Blais C
Anal Chem; 2017 Dec; 89(24):13382-13390. PubMed ID: 29099167
[TBL] [Abstract][Full Text] [Related]
17. Is globotriaosylceramide a useful biomarker in Fabry disease?
Young E; Mills K; Morris P; Vellodi A; Lee P; Waldek S; Winchester B
Acta Paediatr Suppl; 2005 Mar; 94(447):51-4; discussion 37-8. PubMed ID: 15895713
[TBL] [Abstract][Full Text] [Related]
18. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients.
Manwaring V; Boutin M; Auray-Blais C
Anal Chem; 2013 Oct; 85(19):9039-48. PubMed ID: 23968398
[TBL] [Abstract][Full Text] [Related]
19. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.
Auray-Blais C; Blais CM; Ramaswami U; Boutin M; Germain DP; Dyack S; Bodamer O; Pintos-Morell G; Clarke JT; Bichet DG; Warnock DG; Echevarria L; West ML; Lavoie P
Clin Chim Acta; 2015 Jan; 438():195-204. PubMed ID: 25149322
[TBL] [Abstract][Full Text] [Related]
20. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
